Abbott Receives FDA Approval for Creon (pancrelipase) Infant-Specific Dosage for Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Links shared publicly online about this topic.
- 218total visits
Abbott Receives FDA Approval for Creon (pancrelipase) Infant-Specific Dosage for Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Creon (pancrelipase) is used to treat exocrine pancreatic insufficiency. Includes Creon side effects, interactions and indications.
View full resource at drugs.com
Tags: Pancreatic Disease, Cystic Fibrosis, Drug, FDA
Most Recently Shared on June 15, 2011 at 12:08 am By:
Abbott Receives FDA Approval for Creon (pancrelipase) Infant-Specific Dosage for Patients With Exocrine Pa... http://bit.ly/kZWxyW #drug
Abbott Receives FDA Approval for Creon (pancrelipase) Infant-Specific Dosage for Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
drugs.com — “Creon (pancrelipase) is used to treat exocrine pancreatic insufficiency. Includes Creon side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on June 14, 2011 at 11:36 pm By:
FDA Approves Creon (pancrelipase) Infant-Specific Dosage Strength - http://bit.ly/jAdfb4
Advertisement
